Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascendis Pharma A/S (ASND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Ascendis files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which include clinical, regulatory, financial, and corporate information related to its TransCon-based therapies.
In these filings, investors can review details on Ascendis’ pharmaceutical preparation manufacturing activities, including revenue from commercial products such as YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency. Unaudited condensed consolidated interim financial statements, management’s discussion and analysis, and segment information by geography (North America, Europe, and rest of world) are typically included in quarterly 6-K submissions.
Filings also describe the status of key pipeline programs like TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in oncology, along with updates on regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Additional 6-Ks may cover warrant grants, share capital changes, and the operation of equity compensation plans and share repurchase programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 20-F and 6-K filings, helping users quickly understand revenue drivers, operating results, and key clinical or regulatory events. Real-time updates from EDGAR ensure that new Ascendis filings, including financial statements and other material disclosures, are available promptly, while structured access makes it easier to locate specific reports relevant to ASND analysis.
Ascendis Pharma A/S director Lars Holtug has filed an initial statement of beneficial ownership, detailing his equity interests in the company. He reports direct holdings of 4,236 Ordinary Shares, which may be held as American Depositary Shares where each ADS represents one Ordinary Share.
Holtug also holds warrants over 35,000, 7,500, 6,420 and 3,053 underlying Ordinary Shares at exercise prices of 61.0000, 108.0000, 176.2800 and 139.6500 respectively, expiring between November 13, 2028 and December 9, 2031. The warrants are fully vested and currently exercisable.
In addition, he holds restricted stock units covering 1,374, 2,070 and 1,930 underlying Ordinary Shares, each RSU representing a contingent right to receive one ADS. These RSUs vest beginning on March 1, 2027, with some vesting entirely on that date and others in two or three equal annual installments thereafter.
Ascendis Pharma A/S officer SPROGOE KENNETT filed an initial Form 3 showing existing equity holdings, rather than new transactions. The filing lists fully vested and currently exercisable warrants over 5,313, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares at exercise prices of $37.18, $62.17, $108.00, $176.28 and $139.65 per share, respectively. It also reports three blocks of restricted stock units covering 4,246, 3,197 and 9,552 Ordinary Shares, which vest beginning on March 1, 2027 in one‑, two‑ and three‑year installment schedules and have no expiration date. In addition, the officer holds 19,460 Ordinary Shares directly and 110 Ordinary Shares indirectly through children. The footnotes clarify that each restricted stock unit corresponds to a right to receive one American Depositary Share, and each ADS represents one Ordinary Share.
Ascendis Pharma A/S executive Jay Donovan Wu filed an initial Form 3 reporting his equity holdings. He holds warrants covering 45,078 ordinary shares at an exercise price of 131.57 per share expiring on January 14, 2035, restricted stock units for 3,333 and 9,553 ordinary shares that vest in equal annual installments beginning on March 1, 2027, and 1,068 ordinary shares (including ADS) directly.
Ascendis Pharma A/S director Jan Moller Mikkelsen filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. He directly holds 384,933 ordinary shares and indirectly holds 68,470 ordinary shares through Cadenza Partners.
The filing lists several fully vested, currently exercisable warrant series over ordinary shares with exercise prices ranging from 37.18 to 176.28 and expirations from December 2027 through December 2031. It also discloses three restricted stock unit awards over ordinary shares (delivered as ADSs) covering 15,825, 23,834 and 28,945 underlying shares, which vest beginning on March 1, 2027.
Ascendis Pharma A/S officer Jensen Flemming Steen filed an initial ownership report showing a mix of ordinary shares, warrants, and restricted stock units tied to the company’s equity. He holds 19,460 ordinary shares directly, including American Depositary Shares where each ADS represents one ordinary share.
His derivative position includes fully vested, currently exercisable warrants over 20,000, 27,000, 22,755 and 14,504 ordinary shares at exercise prices of 62.1700, 108.0000, 176.2800 and 139.6500 respectively. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest over time beginning on March 1, 2027 and have no expiration date.
Ascendis Pharma A/S director Cha Albert has filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. The filing lists 3,730 ordinary shares held directly. It also discloses fully vested warrants over 542 ordinary shares at an exercise price of $62.1700 expiring on December 11, 2028, 7,500 ordinary shares at $108.0000 expiring on December 10, 2029, 6,420 ordinary shares at $176.2800 expiring on December 10, 2030, and 3,053 ordinary shares at $139.6500 expiring on December 9, 2031. In addition, Cha holds restricted stock units covering 1,374, 2,070 and 1,930 ordinary shares, each representing a right to receive one American Depositary Share, with vesting beginning on March 1, 2027.
Ascendis Pharma A/S executive Shu Aimee, EVP & Chief Medical Officer, filed an initial Form 3 reporting equity holdings in the company. The filing lists direct holdings of restricted stock units (RSUs) convertible into 6,532, 3,197, and 9,552 ordinary shares, plus no directly held ordinary shares. Each RSU represents a right to receive one American Depositary Share, and each ADS represents one ordinary share. The RSUs vest beginning on March 1, 2027, with some grants vesting fully on that date and others in two or three equal annual installments starting then.
Ascendis Pharma A/S reported positive Week 52 topline results from New InsiGHTS, a Phase 2 clinical trial in the U.S. The study compared once-weekly TransCon hGH (lonapegsomatropin) with daily somatropin in prepubertal children with Turner syndrome.
The trial enrolled and dosed 49 children aged 1 to 10 years, who received either the weekly or daily growth hormone regimen. Doses for both treatments were then individualized based on IGF-1 levels to tailor therapy for each child.
Ascendis Pharma A/S reports new 104-week data from its pivotal ApproaCH Trial in children with achondroplasia treated once weekly with TransCon CNP (navepegritide). The data show children maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second treatment year.
The randomized, double-blind, placebo-controlled trial enrolled 84 children aged 2–11 years, with a 52-week placebo-controlled phase followed by an open-label extension to Week 104. TransCon CNP, a prodrug of C-type natriuretic peptide, is designed for continuous CNP exposure to counter overactive FGFR3 signaling.
In February 2026, TransCon CNP was approved by the U.S. FDA under the trade name YUVIWEL to increase linear growth in pediatric patients 2 years and older with achondroplasia and open epiphyses. A Marketing Authorization Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.
Ascendis Pharma A/S reports that its board granted 22,480 warrants to certain employees under its Articles of Association. Each warrant allows the holder to buy one ordinary share at an exercise price of US $240.52, matching the ADS closing price on the grant date.
Twenty-five percent of the warrants vest one year after the grant, with the remaining 75% vesting monthly over the following three years, subject to continued service and possible earlier vesting on certain exit events. After this grant, warrants to subscribe for an additional 1,644,153 shares remain available for future grants.